BioDlink International Company Limited (HKG:1875)
4.200
0.00 (0.00%)
At close: Feb 13, 2026
HKG:1875 Revenue
BioDlink International Company had revenue of 489.14M CNY in the half year ending June 30, 2025, with 49.10% growth. This brings the company's revenue in the last twelve months to 1.07B, up 9.63% year-over-year. In the year 2024, BioDlink International Company had annual revenue of 1.10B with 40.70% growth.
Revenue (ttm)
1.07B CNY
Revenue Growth
+9.63%
P/S Ratio
2.78
Revenue / Employee
1.77M CNY
Employees
604
Market Cap
3.25B HKD
Revenue Chart
* This company reports financials in CNY.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 1.10B | 317.70M | 40.70% |
| Dec 31, 2023 | 780.63M | 338.45M | 76.54% |
| Dec 31, 2022 | 442.18M | 365.85M | 479.34% |
| Dec 31, 2021 | 76.33M | 53.83M | 239.36% |
| Dec 31, 2020 | 22.49M | -22.82M | -50.36% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Hangzhou Jiuyuan Genetic Biopharmaceutical | 1.43B |
| AIM Vaccine | 1.38B |
| Medtide | 546.29M |
| Qyuns Therapeutics | 351.04M |
| Jacobio Pharmaceuticals Group | 220.66M |
| Antengene Corporation | 92.43M |
| Clover Biopharmaceuticals | 56.73M |
| Jiangsu Recbio Technology | 31.90M |